The nonalcoholic steatohepatitis treatment market is evolving rapidly as researchers and pharmaceutical companies strive to address the growing burden of this chronic liver condition. Nonalcoholic steatohepatitis (NASH), characterized by liver inflammation and fibrosis due to fat accumulation, is closely linked to the global epidemics of obesity and type 2 diabetes. With no approved therapies...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian